Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/13/2008

current acute

repetitive seizures in patients with epilepsy. In December 2007, Jazz

Pharmaceuticals dosed the first patient in a Phase II clinical trial of

JZP-8.

-- A single dose pharmacokinetic study of a controlled-release formulation

of JZP-4, a product candidate for the treatment of partial epilepsy and

bipolar disorder, was completed in the fourth quarter of 2007, and

Phase II clinical trial activities are underway.

Jazz Pharmaceuticals will be hosting an Investor Day on March 13, 2008 beginning at 10:00 a.m. Eastern Time/7:00 a.m. Pacific Time. The event will include presentations by Jazz Pharmaceuticals executives and by Dr. Mark H. Pollack, a noted psychiatrist at Massachusetts General Hospital and Professor at Harvard Medical School, who will speak about obsessive compulsive disorder and social anxiety disorder. The event will be available by live audio webcast, and the accompanying presentation materials will also be available on the investor relations section of Jazz Pharmaceuticals' web site at http://www.JazzPharmaceuticals.com.

Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss its financial results and provide a business update on its commercial and development activities on February 13, 2008 commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast may be accessed on Jazz Pharmaceuticals' website at http://www.JazzPharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. An archived version of the webcast will be available through February 27, 2008. Investors may participate in the conference call by dialing 1-800-299-0148 in the U.S., or 1-617-801-9711 outside the U.S., and entering
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Ind. -- Chemists at Indiana University Bloomington have ... bricks-and-mortar fashion, a development with potential value for ... field-effect transistors and photovoltaic cells. , Their paper, ... Crystalline Solids and 2D Self-Assembled Crystals," has been ... journal of the Royal Society of Chemistry. It ...
(Date:7/31/2014)... 31, 2014 Rogne Bioscience, a privately-held biotechnology ... , has acquired a licence to anti-inflammatory peptides ... The potent anti-inflammatory activity of the peptides was discovered ... of Oxford,s Sir William Dunn School of ... over $1.5 million in seed financing, is developing a ...
(Date:7/31/2014)... According to a new market ... Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG ... Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, ... the global electrodes market for medical devices was valued ... to reach a market worth USD 1,451.2 million in ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... its potential as a near-term generator of energy efficiencies ... Phillips, director of the Physical, Chemical, and Nano Sciences ... annual meeting. The meeting runs Feb. 18-22 in San ... that solid-state lighting can better utilize existing energy sources ...
... ... ... ... ...
... , MONTREAL , Feb. ... and advanced chemicals technology company, today announced that Mr. ... Vice-President and Chief Financial Officer. , Mr. Ouimet brings ... of executives, with substantial experience in corporate strategy, corporate ...
Cached Biology Technology:CHMP Adopts Negative Opinion for ZEFTERA(TM) 2CHMP Adopts Negative Opinion for ZEFTERA(TM) 3Enerkem appoints new Chief Financial Officer 2
(Date:7/30/2014)... regulate its genes, and adapt to changes in its ... regulation taking place in the truffle, is published in ... illustrates how the truffle deals with its complex genome,s ... may shed light on how traits like aroma and ... known as Prigord truffles, have a syrupy sweet flavor ...
(Date:7/30/2014)... and tended her eggs until they hatched 4.5 years ... in the open-access journal PLOS ONE by ... colleagues. , Octopuses typically have a single reproductive period ... care of their fertilized eggs until they hatch. Shallow-water ... 3 months, but little is known about the brooding ...
(Date:7/30/2014)... Scientists studying the potential effects of climate change ... focusing on the wrong factors, according to a ... Wildlife Conservation Society, University of Queensland, and other ... conservation science is missing the point when it ... majority of climate change scientists focus on the ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Deep-sea octopus has longest-known egg-brooding period 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... Evolutionary biologist Harmit Singh Malik, Ph.D., of Fred Hutchinson ... the Lupus Research Institute to study the potential role ... autoimmune disease. , Malik and colleagues want to find ... autoimmunity., "We want to determine whether autoimmunity when ...
... Parkinson,s and Alzheimer,s is set to take a step ... analysis using automated 3D microscopy. An initiative ... the Eskitis Institute for Cellular and Molecular Biology, the ... of cells as complex as nerve cells in the ...
... A new study led by the University of North ... starting at age 6 months in high-risk infants who later ... autism. "It,s a promising finding," said Jason J. Wolff, ... at UNC,s Carolina Institute for Developmental Disabilities (CIDD). "At this ...
Cached Biology News:Did an evolutionary arms race cause lupus? Biologist Harmit Malik receives grant to try and find out 2Brain-imaging differences evident at 6 months in infants who develop autism 2
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
... WesternBreeze Immunodetection Kits are designed for ... on nitrocellulose or PVDF membranes. Since ... membranes and primary antibodies), the WesternBreeze ... optimizing your protocol and getting your ...
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: